3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Prostatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
pembrolizumab
75
Nivolumab
46
Cyclophosphamide
25
aldesleukin
23
fludarabine
16
atezolizumab
15
Ipilimumab
15
Interleukin-2
14
Radiosurgery
13
Paclitaxel
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
11
Carboplatin
11
fludarabine phosphate
9
Docetaxel
9
durvalumab
8
Cisplatin
8
cemiplimab
7
Bevacizumab
7
Radiotherapy
6
Gemcitabine
6
Biopsy
6
spartalizumab
5
avelumab
5
Pemetrexed
5
Oxaliplatin
5
Immune Checkpoint Inhibitors
5
Filgrastim
5
Cryosurgery
5
Blood Specimen Collection
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Phlebotomy
×
Genitourinary
×
Clear all
NCT04154163
2022-02-28
ADOPT
University of Dundee
Completed
18 enrolled